Facio’s Managing Director, David Dasberg, passes away suddenly

Leiden, the Netherlands – January 17, 2019 

Facio Therapies announced today that David Dasberg, its Managing Director, passed away unexpectedly on January 16. David suffered a fatal heart attack during a walk in the Dolomite mountains in Northern Italy, where he was vacationing with friends. David had served as Managing Director since Facio’s inception in September 2014. He was 52 years old.

Kees van der Graaf, Facio’s Chairman, said: “All of us at Facio are deeply shocked by David’s sudden passing. He leaves a big void in a closely knit team. David combined a quick and razor-sharp mind with deep expertise, great integrity and total dedication to Facio’s mission. We will remember him as a shining example of what people can accomplish when they pursue a cause in which they truly believe. Without him, Facio would not have been where it is today, and we will build on his legacy as we move forward. Our thoughts go out to David’s loved ones, especially his mother.”

For the time being, David’s responsibilities will be assumed by Otto Postma. Otto is Managing Director of Facio’s parent company, FSHD Unlimited.

About Facio Therapies BV
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4. Facio works with leaders in the field to develop a safe, effective and affordable FSHD therapy in the most expeditious fashion possible. Rooted in, and dedicated to working for the FSHD community, Facio’s business approach is to have a positive impact on lives rather than to maximize financial gain. Since inception, Facio has raised over €16M in equity funding from FSHD-affected families, their friends, FSHD foundations, and Facio’s drug discovery partner, Evotec. Facio’s Board consists of business leaders from the FSHD community – Kees van der Graaf (Netherlands), Neil Camarta (Canada), Dave Mackay (USA), Bill Moss (Australia), and Chip Wilson (Canada) – and Evotec’s CSO, Cord Dohrmann (Germany).